Teva Pharmaceutical Industries Limited

Informe acción NYSE:TEVA

Capitalización de mercado: US$19.4b

Teva Pharmaceutical Industries Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Teva Pharmaceutical Industries de 65.8% y 2.5% por año respectivamente. Se prevé que el BPA crezca en un 60.3% al año. Se espera que la rentabilidad financiera sea de 30.8% en 3 años.

Información clave

65.8%

Tasa de crecimiento de los beneficios

60.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals23.7%
Tasa de crecimiento de los ingresos2.5%
Rentabilidad financiera futura30.8%
Cobertura de analistas

Good

Última actualización14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Nov 17
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Oct 23

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Oct 21
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Cheap Teva Stock Should Reward Patient Investors

Sep 09

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Aug 14

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Jul 26

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Jul 12
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Jun 07

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 14
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)

May 09

Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Mar 26
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Mar 25

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

Feb 26

A Review Of Teva's Prospects

Feb 15

Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Jan 07
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way

Dec 11
These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

Dec 08

Teva: Deeply Undervalued FCF Machine

Nov 20

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Sep 14

Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt

Sep 09
Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Aug 26

Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain

Aug 02

Teva Pharmaceutical: Lacking Capabilities For Strategic Investments

Jul 20

Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence

Jun 15

Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load

Jun 06
Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Feb 20
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

What To Expect From Teva Pharmaceutical In 2023 With A New CEO

Feb 15

Can Teva Pharmaceutical's Q4 results bring positive surprise?

Feb 07

Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment

Jan 19

Tamiflu supplies released from national stockpile as nationwide shortage persists

Jan 12

Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year

Dec 28

Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex

Dec 16

Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit

Nov 10

Previsiones de crecimiento de beneficios e ingresos

NYSE:TEVA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202617,4819643,4351,1728
12/31/202517,0225853,0021,6519
12/31/202416,386-6442,4242949
9/30/202416,772-9591,3681,856N/A
6/30/202416,290-4536791,168N/A
3/31/202416,004-4788781,389N/A
12/31/202315,846-5598421,368N/A
9/30/202315,273-2,3366081,157N/A
6/30/202315,017-2,3501,1731,695N/A
3/31/202314,925-1,7119641,494N/A
12/31/202214,925-2,4461,0421,590N/A
9/30/202215,141-1,2915141,073N/A
6/30/202215,433-1,0544761,059N/A
3/31/202215,557-6155851,154N/A
12/31/202115,878417236798N/A
9/30/202116,23172688673N/A
6/30/202116,324-3,915-131451N/A
3/31/202116,284-3,982-94506N/A
12/31/202016,659-3,9906381,216N/A
9/30/202016,673-4,0319021,423N/A
6/30/202016,78848941,441N/A
3/31/202017,095-825413941N/A
12/31/201916,887-999223748N/A
9/30/201916,396-4,048-42577N/A
6/30/201916,831-4,00784673N/A
3/31/201917,355-3,5594491,062N/A
12/31/201818,271-2,3991,7952,446N/A
9/30/201819,693-11,0592,2332,938N/A
6/30/201820,781-10,256N/A3,312N/A
3/31/201821,800-16,050N/A3,585N/A
12/31/201721,853-16,525N/A2,225N/A
9/30/201723,479-5,963N/A2,791N/A
6/30/201723,425-6,145N/A3,457N/A
3/31/201722,74378N/A3,985N/A
12/31/201621,90368N/A3,890N/A
9/30/201620,2921,591N/A5,415N/A
6/30/201619,5521,346N/A5,047N/A
3/31/201619,4801,697N/A5,564N/A
12/31/201519,6521,573N/A5,542N/A
9/30/201519,9391,775N/A5,679N/A
6/30/201520,1742,548N/A6,010N/A
3/31/201520,2532,757N/A5,583N/A
12/31/201420,2723,055N/A5,127N/A
9/30/201420,5342,748N/A4,191N/A
6/30/201420,5352,583N/A3,211N/A
3/31/201420,4141,383N/A3,033N/A
12/31/201320,3141,269N/A3,237N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TEVA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que TEVA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que TEVA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (2.5% al año) de TEVA crezcan más despacio que el mercado de US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 2.5% al año) de TEVA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de TEVA sea alta dentro de 3 años (30.8%)

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y